
1. j oncol pharm pract. 2013 jun;19(2):181-5. doi: 10.1177/1078155212448408. epub
2012 may 25.

successful clearance cutaneous acyclovir-resistant, foscarnet-refractory
herpes virus lesions topical cidofovir allogeneic hematopoietic stem
cell transplant patient.

muluneh b(1), dean a, armistead p, khan t.

author information: 
(1)department pharmacy, university north carolina hospitals clinics,
chapel hill, nc 27514, usa. bmuluneh@unch.unc.edu

cidofovir deoxycytidine monophosphate analog broad spectrum activity
against various deoxyribonucleic acid viruses. cidofovir marketed an
injectable intravenous use; however, topical cidofovir formulation
utilized viral dermatologic infections. here, present case a
successful clearance perianal acyclovir resistant foscarnet refractory
herpes simplex virus (hsv1) ulcer 34 year-old woman undergone
allogeneic hematopoietic stem cell transplantation. 1 week therapy 
cidofovir gel, patient's ulcer clinically improved, lesion was
negative herpes simplex virus transcripts real-time polymerase chain
reaction testing. wound remained herpes simplex virus negative real-time
polymerase chain reaction repeat testing 1 week later. based other
reports hiv/aids patients, believe cidofovir gel utility the
management cutaneous, acyclovir-resistant hsv infections.

doi: 10.1177/1078155212448408 
pmid: 22635417  [indexed medline]

